Treatment with natalizumab, a blocking antibody against the adhesion molecule integrin α4 and thereby a putative inhibitor of leukocyte transmigration to the CNS [77,78], was found to be associated with reduced CSF levels of CCL22, while CCL17 was below the detection threshold in MS patients before and after natalizumab treatment. Here, CCL17 is linked to myeloid sarcoma.